JUST IN: Pfizer's COVID-19 pill treatment reduces risk of being hospitalized or dying by 89%, company says.
The pharmaceutical company said early trial results of its anti-viral COVID pill, PAXLOVID, reduces risk of being hospitalized or dying by 89%.A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results released Friday by the pharmaceutical company.
Pfizer CEO Albert Bourla said in prepared remarks that the data suggest the pill-based treatment, if authorized, could"eliminate up to nine out of ten hospitalizations." Pfizer's pill-based treatment"would be a good drug for patient with COVID and high risk of progression, vaccinated or not," said Del Rio,"although the vaccinated were not included in this study.", having already applied with the Food and Drug Administration for authorization. Emergency use authorization for the Merck treatment may come before the end of the year.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%(Reuters) -Pfizer Inc's experimental antiviral pill to treat COVID-19 was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday, offering what could be a promising new weapon in the fight against the pandemic. The trial's results suggest that the oral drug surpasses Merck & Co Inc's pill, molnupiravir, which was shown last month to halve the risk of dying or being hospitalized for COVID-19 patients at high risk of serious illness. Pfizer's pill, with the brand name Paxlovid, could secure U.S. regulatory approval by the end of the year.
Lire la suite »
Pfizer says its antiviral pill slashes risk of severe COVID-19 by 89%Pfizer Inc's experimental antiviral pill to treat COVID-19 was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday, offering what could be a promising new weapon in the fight against the pandemic.
Lire la suite »
Pfizer's COVID-19 pill, Paxlovid, cuts hospitalizations, deaths by 89%'An extraordinary effect': Pfizer says its COVID-19 pill reduced the risk of hospitalization and death by 89% in high-risk patients
Lire la suite »
Pfizer: Antiviral pill cuts risk of severe Covid by 89% – latest updatesPfizer says antiviral pill cuts rate of hospitalisation, death by 89 percent. Other Covid19 updates: 🇩🇪 Germany sees second straight case record 🇰🇷 South Korea buys 30M doses of Pfizer's vaccine for 2022 🇯🇵 Japan eases border rules More here:
Lire la suite »
Covid: Pfizer says antiviral pill 89% effective in high risk casesThe company stopped clinical trials early because initial results for the drug were so positive.
Lire la suite »
Pfizer Says Its COVID-19 Pill Is Highly EffectiveAn experimental antiviral pill appears to work very well at keeping people who are at high risk of severe COVID-19 from being admitted to the hospital and dying, according to the drug’s maker, Pfizer.
Lire la suite »